SCHEMBL29732821

SCHEMBL29732821

CC(=O)N[C@H]1[C@H]([C@H](O)[C@H](O)CO)O[C@@](O[C@H](CO)[C@@H](O)[C@@H]2O[C@@](O[C@H]3[C@@H](O)[C@@H](CO)O[C@@H](O[C@H]4[C@H](O)[C@@H](O)C(O)O[C@@H]4CO)[C@@H]3O)(C(=O)O)C[C@H](O)[C@H]2NC(C)=O)(C(=O)O)C[C@@H]1O

nearest known ligand 0.76

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ SIGLEC7 Q9Y286 6/20 0.76
▸ SELP P16109 2/20 0.63
▸ SELL P14151 1/20 0.63
▸ MAG P20916 9/20 0.62
▸ SELE P16581 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29378134 1.00 SIGLEC7 (0.76) SIGLEC7SELPSELLMAGSELE
SCHEMBL29390293 1.00 SIGLEC7 (0.76) SIGLEC7SELPSELLMAGSELE
SCHEMBL30650364 0.98 SIGLEC7 (0.76) SIGLEC7SELPSELLMAGSELE
SCHEMBL31700276 0.98 SIGLEC7 (0.74) SIGLEC7SELPSELLMAGSELE
SCHEMBL31700681 0.97 SIGLEC7 (0.75) SIGLEC7SELPSELLMAGSELE
SCHEMBL31700314 0.97 SIGLEC7 (0.73) SIGLEC7SELPSELLMAGSELE
SCHEMBL31700344 0.97 SIGLEC7 (0.75) SIGLEC7SELPSELLMAGSELE
SCHEMBL31179876 0.97 SIGLEC7 (0.73) SIGLEC7SELPSELLMAGSELE
SCHEMBL31700290 0.97 SIGLEC7 (0.75) SIGLEC7SELPSELLMAGSELE
SCHEMBL31700527 0.97 SIGLEC7 (0.73) SIGLEC7SELPSELLMAGSELE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260139285-A1 SACCHARIDE IMPORTERS FOR LACTO-N-TRIOSE INBIOSE N V (BE) 2026-05-21 — — US disclosed
US-20250361477-A1 PRODUCTION OF AN OLIGOSACCHARIDE MIXTURE BY A CELL INBIOSE NV (BE) 2025-11-27 — — US disclosed
US-12344875-B2 Sialyltransferases for the production of sialylated oligosaccharides INBIOSE N.V. (BE) 2025-07-01 — — US disclosed
US-20250188503-A1 SIALYLTRANSFERASES FOR THE PRODUCTION OF SIALYLATED OLIGOSACCHARIDES INBIOSE N.V. (BE) 2025-06-12 — — US disclosed
US-20250188504-A1 PRODUCTION OF A MIXTURE OF MAMMALIAN MILK OLIGOSACCHARIDES BY A CELL INBIOSE N.V. (BE) 2025-06-12 — — US disclosed
US-20250109419-A1 SIALYLTRANSFERASES FOR THE PRODUCTION OF SIALYLATED OLIGOSACCHARIDES INBIOSE N.V. (BE) 2025-04-03 — — US disclosed
US-20250043253-A1 SIALYLTRANSFERASES FOR THE PRODUCTION OF SIALYLATED OLIGOSACCHARIDES INBIOSE N.V. (BE) 2025-02-06 — — US disclosed
US-20240368651-A1 CELLULAR PRODUCTION OF DI- AND/OR OLIGOSACCHARIDES INBIOSE N.V. (BE) 2024-11-07 — — US disclosed
US-20240327888-A1 LACTO-N-BIOSE CONVERTING FUCOSYLTRANSFERASES INBIOSE N.V. (BE) 2024-10-03 — — US disclosed
US-20240294959-A1 CELLULAR PRODUCTION OF BIOPRODUCTS INBIOSE N.V. (BE) 2024-09-05 — — US disclosed
US-20240209405-A1 PRODUCTION OF A SIALYLATED OLIGOSACCHARIDE MIXTURE BY A CELL INBIOSE N.V. (BE) 2024-06-27 — — US disclosed
US-20240200021-A1 CELLULAR PRODUCTION OF SIALYLATED DI- AND/OR OLIGOSACCHARIDES INBIOSE N.V. (BE) 2024-06-20 — — US disclosed
US-20240191270-A1 FERMENTATIVE PRODUCTION INBIOSE N.V. (BE) 2024-06-13 — — US disclosed
US-20240035055-A1 PROCESS FOR PURIFICATION OF AN OLIGOSACCHARIDE SOLUTION PRODUCED BY CELL CULTIVATION OR MICROBIAL FERMENTATION INBIOSE N.V. (BE) 2024-02-01 — — US disclosed
US-20240011062-A1 METHOD TO PRODUCE A PURIFIED MIXTURE OF DIFFERENT OLIGOSACCHARIDES PRODUCED BY CELL CULTIVATION OR MICROBIAL FERMENTATION INBIOSE N.V. (BE) 2024-01-11 — — US disclosed
US-20230313252-A1 CELLULAR PRODUCTION OF SIALYLATED DI AND/OR OLIGOSACCHARIDES INBIOSE N.V. (BE) 2023-10-05 — — US disclosed
US-20230287470-A1 PRODUCTION OF OLIGOSACCHARIDE MIXTURES BY A CELL INBIOSE N.V. (BE) 2023-09-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260139285-A1 SACCHARIDE IMPORTERS FOR LACTO-N-TRIOSE GALNT3, NANS, ENGASE SIGLEC7 512/4885SELP 621/4885SELL 599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback